CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC)
Market Cap: 130.68M
Outstanding Shares: 28M
Analysis: CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. The removal of the full clinical hold is a positive for the company allowing them to move forward with new trials.
SEATTLE, Jan. 5, 2017 /PRNewswire/ — CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that the full clinical hold (February 2016) implemented by the U.S. Food and Drug Administration (FDA) on all clinical trials conducted under the Investigational New Drug (IND) application for pacritinib has now been removed. Read more…
UPTICK Newswire LLC is not an investment advisor. Investors are strongly encouraged to do their own due diligence and review all company documents and press releases to ensure the company noted above fits their own investment qualifications.
Source: Uptick Newswire